anti human fgfr3 antibody cross reactivity

#Anti human fgfr3 antibody cross reactivity pdf

239000003937 drug carrier Substances 0.000 claims description 24.239000008194 pharmaceutical composition Substances 0.000 claims description 32.

102000005632 Single-Chain Antibodies Human genes 0.000 claims description 32.108010070144 Single-Chain Antibodies Proteins 0.000 claims description 32.108010081291 Type 1 Fibroblast Growth Factor Receptor Proteins 0.000 claims description 44.108010045030 monoclonal antibodies Proteins 0.000 claims description 48.102000005614 monoclonal antibodies Human genes 0.000 claims description 48.201000005112 urinary bladder cancer Diseases 0.000 claims description 52.206010005003 Bladder cancer Diseases 0.000 claims description 84.108010081267 Type 3 Fibroblast Growth Factor Receptor Proteins 0.000 claims description 174.230000001419 dependent Effects 0.000 claims abstract description 48.108020003175 receptors Proteins 0.000 claims abstract description 98.102000005962 receptors Human genes 0.000 claims abstract description 98.

239000003446 ligand Substances 0.000 claims abstract description 100.230000027455 binding Effects 0.000 claims abstract description 202.108010081268 Type 2 Fibroblast Growth Factor Receptor Proteins 0.000 claims abstract description 222.108091008101 FGF receptors Proteins 0.000 title abstract description 184.102000027757 FGF receptors Human genes 0.000 title abstract description 184.230000004913 activation Effects 0.000 title claims abstract description 66.108090001123 antibodies Proteins 0.000 title claims abstract description 388.102000004965 antibodies Human genes 0.000 title claims abstract description 388.Assignors: ROM, ERAN, YAYON, AVNER Application granted granted Critical Publication of US8101721B2 publication Critical patent/US8101721B2/en Status Active legal-status Critical Current Adjusted expiration legal-status Critical Links ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNOR'S INTEREST. PREVIOUSLY RECORDED ON REEL 023537 FRAME 0496. CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNEE FROM FIBRON LIMITED TO FIBRON LTD. Assignors: ROM, ERAN, YAYON, AVNER Publication of US20100047251A1 publication Critical patent/US20100047251A1/en Assigned to FIBRON LTD. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US81369706P external-priority Application filed by Fibron Ltd filed Critical Fibron Ltd Priority to US12/304,638 priority Critical patent/US8101721B2/en Assigned to FIBRON LIMITED reassignment FIBRON LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Original Assignee Fibron Ltd Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) ( en Inventor Avner Yayon Eran Rom Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active, expires Application number US12/304,638 Other versions US20100047251A1

#Anti human fgfr3 antibody cross reactivity pdf

Google Patents Antibodies blocking fibroblast growth factor receptor activation and methods of use thereofĭownload PDF Info Publication number US8101721B2 US8101721B2 US12/304,638 US30463807A US8101721B2 US 8101721 B2 US8101721 B2 US 8101721B2 US 30463807 A US30463807 A US 30463807A US 8101721 B2 US8101721 B2 US 8101721B2 Authority US United States Prior art keywords antibody fgfr2 fgfr3 pro affinity Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US8101721B2 - Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof US8101721B2 - Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof